Drug Profile
Buprenorphine sublingual - Benuvia Therapeutics
Alternative Names: Buprenorphine sublingual spray - INSYS TherapeuticsLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator INSYS Pharma
- Developer INSYS Therapeutics, Inc
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Postoperative pain
Most Recent Events
- 23 Mar 2021 Preregistration development for Postoperative pain is ongoing in USA (Benuvia Therapeutics pipeline, March 2021)
- 23 Mar 2021 Benuvia Therapeutics has patent protection for buprenorphine sublingual spray (Benuvia Therapeutics pipeline, March 2021)
- 27 Jul 2018 INSYS Therapeutics receives a complete response letter from the US FDA for Buprenorphine sublingual spray in post-operative-pain